Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Future Med Chem. 2012 Mar;4(3):289–296. doi: 10.4155/fmc.11.185

Figure 5. In vitro and in vivo assays of ultralow MW heparins.

Figure 5

(A) In vitro anti-Xa activity determination using a chromogenic substrate and (B) in vivo pharmacokinetics profiles in rabbits. Arixtra® (circle), ultralow MW heparins construct 1 (triangle) and ultralow MW heparins construct 2 (diamond).

Reproduced with permisssion from [47].